Inovio Pharmaceuticals (INO -22.7%) slumps on modestly higher volume on the heels of its Q2 report released after the close yesterday that was apparently light on updated information related to COVID-19 vaccine candidate INO-4800.
A Phase 2/3 study should launch next month.
The company is working to expand production capacity to at least 100M doses in 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.